The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

It has the potential to cure MDS. Learn more about our stem cell transplantation program. Stem cell transplants may be considered as a treatment option if you are below the age of 75 and are otherwise ...

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the FDA for the blood cancer.

Several other diseases can be confused with MDS, including: aplastic anemia certain leukemias, including acute leukemia and large granular lymphocytic leukemia HIV infection an overactive immune ...

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat. A briefing document (PDF ...

In support of a central role for NKT cells, a pilot clinical study reported that lenalidomide (an approved treatment for MDS) increased NKT cell numbers in patients with MDS, and several in vitro ...

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Dr. Markku Jalkanen, Faron's CEO, stated, "The FDA's recognition of bexmarilimab for MDS underscores the drug's potential to fulfill a critical need in the treatment of this condition. We ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

Faron Pharmaceuticals Ltd | Company announcement | March 03, 2025 at 14:00:00 EET Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS Key highlights Orphan Drug ...